Receive a complete Daily History of this Stock You can receive a complete daily file of this issue since 1970 or stock inception. We will email you the file in ASCII format within a few hours or ordering. Product Details | Order

Business Description
Gen-Probe Incorporated develops, manufactures and markets nucleic acid probe-based products used for the clinical diagnosis of human diseases and for screening donated human blood (nucleic acid testing, or NAT). NAT enables detection of microorganisms that are difficult or time-consuming to detect with traditional laboratory methods. The Company generates revenues primarily from sales of clinical diagnostic and blood screening assays. Its clinical diagnostic products are marketed to laboratories and public health institutions in the United States and Canada through its direct sales force. Gen-Probe has agreements with Chiron, Bayer, bioMérieux and Fujirebio, through its subsidiary Rebio Gen, Inc., to market some of its clinical diagnostic products in various global markets. For the year ended December 31, 2003, product sales, collaborative research revenues and royalty and license revenues equaled 91%, 7% and 2%, respectively.

Financial Information
For the nine months ended 9/30/04, revenues rose 35% to $201.2 million. Net income rose 66% to $42.6 million. Results reflect higher sales of commercial blood screening products and improved margins.